Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Revision of Precautions

Trelagliptin succinate

September 6, 2019

Therapeutic category

Antidiabetic agents

Non-proprietary name

Trelagliptin succinate

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

<table>
<tr><th>Current</th><th>Revision</th></tr>
<tr><td>
Contraindications
Patients with severe renal impairment or patients with end stage renal failure on dialysis (Zafatek is mainly excreted from the kidney, and the blood concentration of Zafatek may increase due to delay in the excretion.)

Precautions concerning Dosage and Administration
Patients with moderate renal impairment should reduce the dose according to the table below as a delay in excretion may increase the blood concentration of this drug. (Refer to the “Pharmacokinetics” section)

Dosage for patients with moderate renal impairment
<table>
<tr><th></th><th>Serum creatinine (mg/dL)*</th><th>Creatinine clearance (Ccr, mL/min)</th><th>Dosage</th></tr>
<tr><td>Patients with moderate renal impairment</td><td>Men:1.4 < to ≤ 2.4
Women:1.2 < to ≤ 2.0</td><td>30 ≤ to < 50</td><td>50 mg, once weekly</td></tr>
</table>
*: Converted level equivalent to Ccr (age: 60 years old, body weight: 65 kg)
</td><td>
Contraindications
(deleted)

Precautions concerning Dosage and Administration
Patients with moderate or severer renal impairment should reduce the dose according to the table below according to patients’ renal function level, as a delay in excretion may increase the blood concentration of this drug. (Refer to the “Pharmacokinetics” section)

Dosage for patients with moderate or severer renal impairment
<table>
<tr><th></th><th>Serum creatinine (mg/dL)*</th><th>Creatinine clearance (Ccr, mL/min)</th><th>Dosage</th></tr>
<tr><td>Patients with moderate renal impairment</td><td>Men:1.4 < to ≤ 2.4, women:1.2 < to ≤ 2.0</td><td>30 ≤ to < 50</td><td>50 mg, once weekly</td></tr>
<tr><td>Patients with severe renal impairment/patients with end stage renal failure</td><td>Men: > 2.4
Women: > 2.0</td><td>< 30</td><td>25 mg, once weekly</td></tr>
</table>
A temporal association between Zafatek and hemodialysis is not considered for patients with end stage renal failure.
*: Converted level equivalent to Ccr (age: 60 years old, body weight: 65 kg)
</td></tr>
</table>

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Careful administration (Zafatek should be administered with care in the following patients) Patients with the following conditions: Patients with moderate renal impairment	Careful administration (Zafatek should be administered with care in the following patients) Patients with the following conditions: Patients with moderate or severer renal impairment or patients with end stage renal failure on dialysis (The blood concentration of Zafatek may increase, depending on the renal function level. The dosage of Zafatek should be reduced and the condition of the patient be carefully monitored.)

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp